Bothell, United States
AGC Biologics, founded in 2001, is a prominent global player in the biopharmaceutical sector, specifically operating as a Contract Development and Manufacturing Organization (CDMO). The company epitomizes excellence by adhering to high service standards and builds robust partnerships with its clients to advance biopharmaceutical innovations.
The company's core expertise lies in the development and manufacturing of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cell therapies. This diverse product portfolio underscores its formidable presence in the Biotechnology, Industrial, and Manufacturing industries.
With a strategic global footprint, AGC Biologics operates cGMP-compliant facilities in key regions of the U.S., Europe, and Asia, enhancing its capacity to meet diverse client needs. This expansive network includes facilities in Seattle, Copenhagen, Heidelberg, Milan, Chiba, and Yokohama.
The company’s absence of recent investment activity suggests a stable operational capability, potentially presenting a mature opportunity for investors seeking to engage in the growing biopharmaceutical manufacturing sector.
